The Hygiology Post ® is presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; retrieved on 12-28-2013). As a matter of disclosure : The author continues to be a current shareholder in the company.
A recent article in the publication, Seeking Alpha (https://seekingalpha.com/article/1917121-senesco-near-term-catalyst-could-double-shareprice; obtained on 12-28-13), titled “Senesco: Near-Term Catalyst Could Double Shareprice” on “Dec. 26, 2013 11:12 AM ET” by identified contributor John H. Ford began the following way:
“Disclosure: I am long OTCQB:SNTI, OPK. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…)
I initiated coverage on Senesco (OTCQB:SNTI) four months ago when it was trading at $3. Shares rose above $7, but have since retreated. This provides an ideal opportunity for investors because since my last article, 2 positive events have occurred:
Number 1: Senesco just reported excellent data for cohort 3 of the current clinical trial. This milestone event takes Senesco one step closer to addressing the $75 billion cancer drug market.
Number 2: Opko’s (OPK), Dr. Phillip Frost just initiated a 9.99% position in Senesco. As some of my readers know, all my Dr. Frost investments have provided returns above 100%. For example, soon after Dr. Frost initiated a position in MusclePharm (OTCQB:MSLP), the stock went from $4 to $13.
Dr. Frost and his team are capable of conducting a very high level of due diligence, and his investment in Senesco is a strong validation of the company’s management and technology. It’s probably not coincidental that Dr. Frost initiated his Senesco position immediately after the positive cohort 3 data was announced. One also has to wonder if Opko could beinterested in acquiring Senesco.
Near-term catalyst could more than double shareprice
In my opinion, another reason for Dr. Frost’s new position in Senesco, is because in about 3 months, Senesco will be releasing the results for cohort 4 of its current clinical trial. Positive results could have a significant effect on the share price because this would be the point at which Big Pharma could begin making serious buyout or partnership offers.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2013 The Hygiology Post ®